NEJMJClub
Tozorakimab to Prevent COPD Exacerbations.
New England Journal of Medicine · · Randomized Controlled Trial
Sciurba, Watz + more
Abstract ↗AI summary
The abstract is read at the publisher; the summary is JClub's.
In two phase 3 COPD trials, add-on tozorakimab 300 mg every 4 weeks reduced the annualized moderate/severe exacerbation rate versus placebo, with rate ratios 0.71 and 0.66.
- Why it matters: Many COPD patients still exacerbate despite stable inhaled maintenance therapy, and dysregulated interleukin-33 signaling is implicated in disease pathogenesis.
- What they did: Adults with COPD who were current or former smokers and had exacerbations in the prior year were randomized to add-on subcutaneous tozorakimab 300 mg or placebo every 4 weeks for 52 weeks in OBERON and TITANIA.
- The result: Among former smokers, annualized rates were 1.34 vs 1.90 (OBERON) and 1.37 vs 2.07 (TITANIA), and in the overall population 1.41 vs 2.00 (OBERON) and 1.44 vs 2.03 (TITANIA), with adverse events reported in 70.4–80.1% on tozorakimab versus 77.2–79.8% on placebo.
The findingWhy it mattersWhat they didThe result
- 4 cites